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Abstract
In recent years there has been exponential growth in the interest in microvesicles, which is
reflected by the number of publications. Initially referred to as “platelet dust” by Peter Wolf in 1967,
platelet microvesicles (PMV) are now recognized as important mediators of intercellular communication.
There are examples of PMV exerting physiological effects on almost all hematological and vascular cell
types, including monocytes, macrophages, neutrophils, T-cells, endothelium cells, and smooth muscle
cells. PMV can exert these effects by multiple methods: extracellular signaling through receptors, transfer
of surface molecules, and delivery of intracellular contents including miRNA. Recent work suggests a
complex environment in which cellular contents are being shared muti-directionally between multiple cell
types. This review will focus on the communicative properties of PMV.

Introduction
Extracellular vesicles (EVs) are membrane bound vesicles produced by almost every type of cell
that resides in or contacts the blood. Many investigators have become interested in EVs for several
reasons: (1) Their quantity increases in many pathological conditions [1]; (2) They participate directly in
physiological processes such as thrombin generation [2]; and (3) they serve as mediators of intercellular
communication, directly affecting the biology of target cells or delivering bioactive molecules. This review
will focus on the role of platelet microvesicles (PMV), one of the most abundant circulating MV, in
intercellular communication [3]. The review will cover advances in the understanding of how PMV interact
with target cells in a variety of modes including lipid-mediated signaling, protein-mediated signaling,
surface receptor transfer, cytosolic content transfer, and miRNA transfer. In addition, the mechanisms by
which PMV are produced and taken up by target cells is briefly summarized.
Production of platelet microvesicles
Platelets produce PMV in response to a large number of stimuli. Complement protein C5b-9,
bacterial lipopolysaccharide, cold storage, and influenza virus H1N1 all have been reported to generate
PMV from exposed platelets [4]. PMV formation is closely connected to the formation of surface
phosphatidylserine (PS) positive, procoagulant platelets. The connection between PS exposure and PMV
formation was first observed in response to platelet stimulation with thrombin or collagen [5]. Since that
report, many investigators have reported that dual stimulation with collagen and thrombin, or a single
agonist combined with shear stress is required for maximal PMV production [6; 7]. While shear alone
does not result in PMV generation, shear plus von Willebrand Factor (vWF) does [8]. The requirement for
vWF for shear-generated PMV is supported by evidence that antibodies that block the vWF receptor,
GIPbα, suppress PMV production [9]. PS exposure and PMV production have also been linked to
elevated cytosolic Ca2+ levels and to the activation of the Ca2+ protease, calpain [6; 7; 10]. PS is normally
located on the inner leaflet of the cellular membrane and exposure requires the action of “flippases” to
transfer the PS to the outer membrane. PS exposure leads to assembly of prothrombinase complexes on
the surface of platelets. A defect in platelet PS exposure leads to the bleeding disorder and defective
PMV release in Scott syndrome patients. TMEM16F, which is mutated in Scott syndrome patients, has
been identified as the Ca2+-dependent flippase responsible for PS-exposure and PMV release [11]. Being
that increased shear, as found at thrombosis sites, plays a role in PMV formation and that PS+ PMV can
generate thrombin, it is a matter of debate whether PMV are a cause or result of thrombosis. Perhaps
PMV serve as a mechanism by which a thrombus is propagated and sustained. In addition to the above
processes, proteasome function, cytoskeletal rearrangement, protein tyrosine phosphatase activity and
outside-in signaling through the platelet fibrin receptor have been implicated in PMV formation [4].
Content of platelet microvesicles
MV cellular origin is determined by surface markers inherited from the parental cell. While
platelet surface proteins such as CD41, CD42, and CD61 are typically used identify PMV, these markers
are present on the platelet precursor, the megakaryocyte, which also produces MVs [8; 12]. Flaumenhaft
and colleagues reported that a majority of MVs generated from platelets expressed CD62P and contained
cleaved filamin A. However most plasma CD41+ MVs did not expressed CD62P and contained both
intact and cleaved filamin A. These data suggest that a significant portion of circulating CD41 + MVs
actually originate from megakaryocytes and not platelets [12].
PMV also contain a wide array of molecules including growth factors, coagulation factors,
enzymes, adhesion molecules, chemokines, cytokines, complement proteins, apoptosis regulators,
bioactive lipids, and miRNAs [1; 13]. PMV are more enriched in PS and P-selectin than the parental
platelet, suggesting either an active process to select content or the occurence of MV budding in specific
regions of the platelet membrane that are enriched for such factors [14]. There is evidence that under

shear stress, platelets form flow induced protrusions (FLIPRs) from which PMV arise, supporting the
hypothesis that PMV arise from specific regions of the platelet membrane [15]. PMV content can differ
depending on the stimulus which generated them. A recent proteomic analysis of PMV identified 3383
proteins. The levels of these proteins were different depending on the agonist that produced the PMV
[16]. In addition, PS content was found to be higher in Ca2+ ionophore A23187 induced PMV compared
to thrombin-stimulated PMV, indicating stimulus-specific membrane composition [17].
Platelet microvesicles as intercellular communication mediators
PMV can interact with other cells in multiple ways: both proteins and bioactive lipids on the
surface of MV have been implicated in triggering receptors on target cells. Fusion of MV and target cells
can lead to the transfer of membrane integral proteins, adding new functions to the larger cell.
Internalization and unpacking results in the delivery of cytosolic enzymes and miRNAs. In addition, there
has been several reports of MV effects on target cells in which the mode of interaction in not known.
Table 1 summarizes the literature of interactions between PMV and target cells.
Lipid-mediated signaling
One of the first descriptions of a mechanism by which PMV activate cells was by Garrett
FitzGerald et al. They reported that arachidonic acid (AA) from PMV induced platelet aggregation and
found the PMV AA was metabolized by the platelet into thromboxane A2 (TXA2). PMV AA also induced
COX-1 expression and prostacyclin PGI2 production [18]. The following year they reported that PMV AA
stimulated an increase in intracellular adhesion molecule-1 (ICAM-1) expression in human umbilical vein
endothelial cells (HUVECs). This increase lead to enhanced monocyte:endothelial interactions. PMV AA
also caused an increase in lymphocyte function–associated antigen-1 (LFA-1) and macrophage antigen-1
(Mac-1) in monocytes and the U-937 monocytic cell line. These changes in surface antigens were
accompanied by enhancement of chemotaxis in U-937 cells [19]. The mechanism for these effects was
later reported to be dependent on the Protein Kinase C (PKC) and Mitogen Activated Protein Kinase
(MAPK) pathways [20]. In contrast to this work, where AA is transferred from PMV to target cells and
metabolized, Sandra Pfister reported that AA is transferred to PMV from rabbit pulmonary artery
endothelial cells. The AA was subsequently metabolized into TXB2 in the PMV. Differences in
experimental approaches and endothelial subtypes may explain this disparity [21].
Kim et al. have reported that treatment of HUVECs with PMV resulted in protection from
apoptosis, enhanced proliferation, and agiogenesis, as measured by tube formation assays. While heat
treatment of the PMV prior to adding them to HUVECs had little result, charcoal treatment resulted in a
significant reduction of these effects. As charcoal treatment removes nonpolar lipids, the authors
reasoned that a lipid component of PMV was responsible for stimulation of HUVECs [22].
Extracellular protein mediated signaling
There have been several studies that describe the PMV-induced effects on cells that are
mediated by signaling proteins. While many of these proteins have been described as membraneassociated, others are not, and it is not clear if these proteins are secreted from the PMV or tethered to
the PMV membrane. Brill et al. reported a pro-angiogentic effect of PMV treatment on rat arotic
endothelial cells, which was dependent on the growth factors Vascular Endothelial Growth Factor
(VEGF), basic Fibroblast Growth Factor (bFGF), and Platelet Derived Growth Factor (PDGF). PMV
VEGF and PDGF also caused endothelial migration in a matrigel assay. This events were mediated via
the Phosphoinositide 3-kinase (PI3K), Src, and Extracellular Regulated Kinase (ERK) pathways [23].
PMV have also been reported to enhance monocyte arrest on endothelial cells. This phenomenon was
dependent on PMV deposition of the cytokine CCL5, also known as RANTES (Regulated on Activation,
Normal T-cell Expressed and Secreted) onto activated endothelium [24].

Eric Boilard et al. reported that PMV in synovial fluid from patients with rheumatoid arthritis
increased production of inflammatory cytokines in fibroblast-like synoviocytes in an IL-1 dependent
manner [25]. PMV influences on inflammatory signaling was also recently discovered by Bei et al. They
found that Staphylococcal superantigen-like protein 5-stimulated platelets produced PMV, which leads an
increase interleukin 1β (IL-1β), Tumor Necrosis Factor α (TNFα), and Monocyte Chemoattractant Protein1 (MCP-1) in monocytes. Neutralizing antibodies to CD40L caused a significant reduction in this
phenomenon [26]. In contrast to the proinflammatory response described above, PMV may also have
anti-inflammatory effects. Exposure to PMV resulted in a decrease in interferon γ (IFNγ), TNFα, and IL-6
secretion in CD4+ T-cells. PMV further caused an increase in Transforming Growth Factor – β1 (TGF-β1)
production and differentiation of naïve CD4+ T-cells to Foxp3+ regulatory T cells. These effects were
mediated by PMV TGF-β1 [27].
Receptor transfer
Another mode in which PMV interface with target cells is membrane fusion. This results in the
transfer of platelet surface proteins to the recipient cell, imparting new functions and immunological
reactivity, potentially confounding identification and purification of cell types. Ratajczak et al. have
reported a series of observations regarding the transfer of platelet surface proteins to various cell types.
They first published their findings that human CD34+ and mouse Sca-1+ hematopoetic stem express
interact with PMV via P-selectin glycoprotein ligand-1 (PSGL-1), which binds with P-selectin on activated
platelets and PMV. This interaction resulted in the transfer of surface platelet proteins, such as CD41,
CD61, CXCR4, and PAR-1. Electron microscopic analysis revealed a lack of intact platelets, suggesting a
PMV-mediated effect. This transfer resulted in improved adhesion of these stem cells to endothelium and
engraftment after transplantation in a murine model [28]. They next found that CXCR4, CD41, and Pselectin could be transferred to erythroblasts, myeloblasts, and monocytes [29]. Finally, they described
how PMV delivery of CXCR4 to erythroblasts or UT-7 myeloid leukemia cells resulted in their ability to
become infected by X4-trophic HIV [30].
PMV-mediated delivery of CXCR4 has been implicated in other processes as well. Transfer to
angiogenic early outgrowth cells augmented pro-angiogenic properties including increased adhesion to
the extracellular matrix and enhanced proliferation, migration and tube formation [31]. Finally, transfer of
the platelet fibrinogen binding integrin, αIIbβ3, by PMV enabled NF-κB signaling in response to GM-CSF
(Granulocyte Macrophage Colony-Stimulating Factor) in neutrophils, potentially enhancing inflammation
[32].
PMV internalization
Membrane fusion between PMV and cells can result in the contents of the PMV being deposited
into the cytosol of the recipient cell. An early mechanistic description of MV:target cell fusion indicated
that monocyte MV (MMV) bound to platelets via P-selectin:PSGL-1 interactions. Blocking PS with
Annexin V did not prevent MMV:platelet association, but did inhibit membrane fusion, indicating a PSdependent mechanism [33]. More recently, MV derived from hypoxia-induced mesenchymal stem cells
(MSC-MV) have been reported to be internalized by HUVECs in a PS-dependent manner [34].
Gas6 is a secreted protein that binds to externalized PS on cells, which then serves as a ligand
for the tyrosine kinase receptors Tyro3, Axl, and Mer (TAMs). Happonen et al. have reported that PMV
internalization by endothelial cells is mediated by interactions between Gas6 and tyrosine receptor kinase
Axl [35]. Other lipid mediators have been implicated in the MV internalization process. The catalytic
activity of secreted phospholipase A2 group IIA (sPLA2-IIA) was found to be necessary for PMV
internalization by neutrophils. sPLA2-IIA can use PMV membranes as a substrate to generate AA. AA
can then be further converted into 12-hydroxyeicosatetraenoic acid (12-HETE) by 12-lipoxygenase (12-

LOX), both of which were required for engulfment as well [36]. Further work remains to be done to better
understand the regulation of MV uptake and to delineate potential differences between MV subtypes.
Transfer of Protein
Ray et al. reported that peroxisome proliferator-activated receptor γ (PPARγ), a ligand-activated
transcription factor involved adipocyte differentiation, could be transferred to a THP-1 monocytic cell line
[37]. Tang et al. demonstrated the PMV contain 12-LOX, which can be delivered to mast cells, where it
leads to enhancement of lipoxin A4 (LXA4) production [38]. LXA4 is a negative regulator of inflammation,
providing additional evidence that PMV can play both a positive and negative role in inflammatory
responses. In an intriguing study, Boudreau et al. provided evidence that a subset of PMV contain
functional mitochondria and that these mitochondria could be transferred to neutrophils [39]. The
physiological consequence of this transfer in uncertain but it suggests the possibility of platelets being
able to provide an “energy boost” to cells under conditions in which PMV are produced.
Transfer of miRNA
miRNAs are approximately 22 nucleotide regulatory RNAs expressed in multicellular organisms [40].
miRBase v21 (June 2014, http://www.mirbase.org/) lists 2588 mature human miRNAs while the
GENCODE reference set (v22) derived from ENCODE data lists 4093 [41], although recent data provides
strong evidence for more than twice that many [42]. MiRNAs regulate most (>60%) mammalian protein
coding genes [43]. Some miRNAs are expressed ubiquitously, but many are tissue and/or developmental
stage specific [42; 44]. Guided by the miRNA sequence, the RNA-induced silencing complex (RISC)
causes translational inhibition followed by mRNA degradation caused by Argonaute (Ago) nucleases [45].
The impact of miRNAs on gene expression is often to fine-tune and reduce noise in protein expression
[46].
Because of the commonality of PMV elevation in cardiovascular disease, the interaction between
PMV and the endothelium has been an area of high interest. In 2013, Gidlöf et al. reported finding miR22, miR-185, miR-320b, and miR-423-5p in the supernatant of activated platelets. These miRNAs were
taken up by the endothelial cell line HMEC-1. This transfer was attenuated in the presence of brefeldin A,
an inhibitor of vesicle formation. Delivery of miR-320b resulted in a downregulation of ICAM-1 expression
in the HMEC-1 cells. While this report did not specify the extracellular vesicle responsible for the transfer,
this was one of the first reports of vesicle-mediated platelet miRNA delivery [47]. A few months later,
Patrick Provost et al. published their finding that PMV contain functional miR-223:Ago2 complexes.
These PMV were internalized by HUVECs where they caused downregulation of miR-223 target mRNAs,
FBXW7 and EFNA1 [48]. PMV-mediated delivery of miR-223 to HUVECs has also been reported to
regulate the expression of the insulin-like growth factor 1 receptor (IGF1R). Downregulation of IGF1R
sensitized the HUVECs to apoptosis caused by advanced glycosylation end products [49].
In addition to endothelial cells, PMV have also been reported to deliver miRNAs to macrophages.
PMV-transferred miR-126-3p to macrophages resulted in lower expression levels of ATF3, ATP1B1,
ATP9A, and RAI14. Of these, lower levels of ATF3 and ATP1B1 protein was confirmed. PMV treatment
of macrophages also resulted decreased secretion of CCL4, Colony Stimulating Factor 1 (CSF1), TNFα,
and enhanced phagocytic activity, although these effects appear to be miR-126-3p independent [50].
Elevated P?MV levels have also been reported in many cancers. PMV-transferred miR-223 to
A549 human lung cancer cells resulted in lower levels of the tumor suppressor erythrocyte membrane
protein band 4.1-like 3 (EPB41L3) mRNA and protein. Lower levels of EPB41L3 lead to enhanced tumor
invasion in a transwell assay [51]. These results indicate the PMV-mediated miRNA delivery can affect
gene expression in conditions beyond cardiovascular disease.
PMV signaling via unknown mediators

Other physiological effects of PMV exposure to cells have been reported without the molecular
mediator of the effect being identified. Exposure to PMV results in neutrophil activation as measured by
CD11b expression and increased phagocytic activity. This activation required PMV P-selectin:neutrophil
PSGL-1 interactions [52]. PMV also stimulated bovine coronary artery smooth muscle cells in a PDGFindependent manner [53]. Finally, exposure of THP-1 cells to PMV resulted in aggregation of those cells
and production of tissue factor positive MV from them [54].
Platelet microvesicle association with cardiovascular disease
An increase in the concentration of PMV has been observed in almost all cardiovascular
conditions, including acute coronary syndromes, arteriosclerosis obliterans, hypertension, type 2
diabetes, and other conditions [1]. MV, including PMV, elicit multiple responses from the endothelium.
Endothelial cell (EC) exposure to PMV induces effects on proliferation, NO production, and angiogenesis
[22]. Multiple reports have indicated that circulating plasma MVs from sick patients are inherently
different from those of healthy subjects, inducing different responses in the cells to which they are
exposed. Boulanger et al. demonstrated that MV from patients with myocardial infarction impaired
endothelium-dependent relaxation, whereas MVs from healthy controls did not [55]. MV from metabolic
syndrome patients elicited less NO production from ECs.[56] Different angiogenic effects were observed
with MV from type 2 diabetic patients compared to controls.[57] Even within an individual, MV isolated by
endarterectomy from atherosclerotic plaques were able to induce proliferation and angiogenesis in EC,
while circulating MV were not [58]. These data indicate that not only do PMV increase in quantity in
pathological conditions, but their effects on external cells are altered. This is perhaps due to changes in
the MV content modifying the signals they relay.

Conclusion
Recent discoveries of the properties of EV reveal a world in which cellular content, including
genetic material, is constantly being exchanged between multiple cell types, both healthy and
pathological. This review has focused on the role of PMV, but there is evidence that MV and exosomes
from many cell types can signal and transfer their content extracellularly. Additionally, it has been
reported that platelets can adsorb RNA from the milieu of tumors, leading to the concept of the platelet as
sentinel for pathological conditions [59]. With the uncovering of this new world of intercellular
communication, analysis of platelet RNA and protein content now must be thought of in context of where
it originated from and where it may be transferred to. Additionally, the novel roles of platelets and platelet
RNA in multiple biological processes and pathological conditions may be uncovered, leading to new
biomarkers and new therapeutic targets.

Table 1. Summary of reported PMV mediated communication events.
Target Cell

MV
molecule(s)

Physiological Consequence

Reference

Platelets

Arachadonic
Acid
Arachadonic
Acid

Aggregation
Thromboxane Generation
Increase in COX-21 expression
Increased surface ICAM-13
expression
Increased monocyte:HUVEC
adhesion
Increased Mac-14 and ITGAL5
expression
Increased Chemotaxis
Enhanced proliferation
Enhanced survival
Enhanced migration
Enhanced tube formation
Endothelial arachidonic acid is
transferred to the MV where it
produces TXB26

[18]

HUVEC2

•
•
•
•

Lipid Mediated
Signaling

•
U-937 macrophage
cell line

Arachadonic
Acid

HUVEC

Activated
charcoal
sensitive
factor
COX-2

Rabbit pulmonary
endothelial cells

•
•
•
•
•
•
•

[19]

[19]

[22]

[21]

•

Protein Mediated
Signaling
Rat aortic
endothelial cells
Activated
Endothelium

VEGF7, bFGF8,
PDGF9
RANTES10

•

Enhanced Angiogenesis

[23]

•
•

[24]

Fibroblast-like
Synoviocytes
Activated CD4+ T
cells

IL-113

•

TGF-β114

•

CD40L17

•
•
•

Enhanced monocyte arrest
Interaction required P-selectin,
GPIb, GPIIb/IIIa11, and JAM-A12
Increased IL-6 and IL-8
production
Decreased release of IFNγ15,
TNFα16, and IL-6
Increased production of TGF-β1
Increased CD25highFoxp3+ Tregs
Increase in inflammatory signals
(IL-1β, TNFα, MCP-118

CD41

•
•

Improved adherence to
endothelium
Improved engraftment
Increased adhesion,
proliferation, and survival
Activate signaling
Enables infection of previously
CXCR4 null cells by HIV22

[28]

Enabled signaling to NF-κB23 in

[32]

Monocytes

Receptor Transfer
• Human CD34
HSC19
• Murine Sca-1+ 20
• Erythroblasts
• Myeloblasts
• Monocytes
• Erythroblasts
• UT-7 myeloid
leukemia cell line
• Neutrophils
+

CXCR421
CD41
CD62
CD41
CXCR4
GPIIb/IIIa

•
•
•
•

•

[25]
[27]

[26]

[29]

[30]

• Angiogenic early
outgrowth cells

CXCR4

•
•

THP-1 monocytic
cell line
Mast cells

•

Neutrophils

PPARγ26/RXR27
complex
12lipoxygenase
Mitochondria

HUVEC
HMEC-1 human
microvascular
endothelial cell line

response to GM-CSF24
Increased adhesion to ECM25
Enhanced proliferation,
migration, and tube formation

[31]

Non-receptor
transfer

l

[37]

•

Capable of DNA binding and
affecting gene expression
Enhanced lipoxin A4 production

•

Unknown

[39]

miR-223

•

[48]

miR-22
miR-185
miR-320b
miR-423-5p
miR-223

•

Downregulation of FBXW728 and
EFNA129 RNA
Reduction of ICAM-1

Downregulation of IGF-1R30
Apoptosis
Downregulation of EPB41L331
Promotion of cell invasion
Downregulation of CCL432,
CSF133, TNFα
Enhanced phagocytic capacity

[49]

Increase in neutrophil activation
as measured by CD11b
expression
Increased phagocytic activity
Required P-selectin:PSGL-134
interaction
Stimulated proliferation

[52]

Aggregation of THP-1 cells
Production of TF+ monocytic
MVs

[54]

[38]

miRNA Transfer

HUVEC
A549 human lung
cancer cell line
Macrophages

miR-223
miR-126-3p

•
•
•
•
•
•

[47]

[51]
[50]

Other/Unknown
effector
•

Neutrophils

•
•
Bovine coronary
artery SMC35
THP-1 monocytic
cell line

PDGF
independent

•
•
•

[53]

Legend: 1 - cyclooxygenase-2, 2 – Human Umbilical Vein Endothelial Cell, 3 – Intercellular Adhesion
Molecule-1, 4 – Macrophage-1 Antigen, 5 -Integrin Subunit Alpha L, 6 – Tromboxane B2, 7 – Vascular
Endothelial Growth Factor, 8 -basic Fibroblast Growth Factor, 9 – Platelet Derived Growth Factor, 10 Regulated on Activation, Normal T cell Expressed and Secreted, 11-Glycoprotein, 12-Junctional
Adhesion Molecule-A, 13 – Interleukin-1, 14 – Transforming Growth Factor - β1, 15 - Interferon γ, 16 –
Tumor Necrosis Factor α, 17 – CD40 Ligand, 18 - Monocyte Chemoattractant Protein-1, 19 –
Hematopoietic Stem Cell, 20 – Stem Cell Antigen-1, 21 – Chemokine Receptor 4, 22 – Human
Immunodeficiency Virus, 23 – Nuclear Factor – κB, 24 - Granulocyte Macrophage Colony-Stimulating

Factor, 25 – Extracellular Matrix, 26 - Peroxisome proliferator-activated receptor, 27 – Rentinoid X
Receptor, 28 - F-Box And WD Repeat Domain Containing 7, 29 – Ephrin A1, 30 - Insulin-Like Growth
Factor 1 Receptor, 31 - Erythrocyte Membrane Protein Band 4.1 Like 3, 32 - C-C Motif Chemokine Ligand
4, 33 - Colony Stimulating Factor 1, 34 - P-Selectin Glycoprotein Ligand-1, 35 – Smooth Muscle Cells
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